What Pattern Bioscience does

Pattern Bioscience is an Austin, Texas-based clinical diagnostics company, founded in 2016 (originally as Klaris Diagnostics) and operating as a privately held Texas corporation. The company has developed a single-cell microbiology platform (branded Digital Culture™) that captures individual live bacterial cells in picovolume-scale droplets and analyzes their metabolic patterns via machine learning to deliver pathogen identification (ID) and antimicrobial susceptibility testing (AST) in hours rather than the 2–4 days required by conventional culture-based methods. Its primary customers are hospital clinical microbiology laboratories serving critically ill patients with suspected bacterial infections, particularly pneumonia, bacteremia, and urinary tract infections, where delays in targeted antibiotic therapy materially increase mortality and accelerate antimicrobial resistance. Pattern's core products are the lead Pneumonia ID/AST Panel, an in-development Bacteremia ID/AST Panel, and the underlying instrument and consumables platform; the platform's phenotypic approach is designed to capture all known and unknown resistance mechanisms rather than relying solely on genotypic markers.

The company is pre-commercial as of early 2026 with no product revenue and planned first U.S. commercial launch following FDA 510(k) clearance; revenue mechanics will rely on direct enterprise sales of the instrument platform and disposable assay panels to U.S. hospital laboratories, supported by a dedicated VP of Sales and product marketing leadership. Pricing is not publicly disclosed. Capitalization exceeds $148M in total funding, including a $28.7M Series C (April 2023), a $43M Series D (November 2025) co-led by AMR Action Fund, Illumina Ventures, and Omnimed Capital, a Form D exempt offering of approximately $61.22M (with $44.22M sold as of August 2025), a $6.8M CARB-X award plus a Series B (February 2020), a $9M Series B-1 (July 2020), and a $3.75M Series A (May 2018); non-dilutive capital is supplemented by a BARDA cost-share contract worth up to $40.9M awarded in November 2024.

Name

Pattern Bioscience

Legal name

Pattern Bioscience, Inc.

Website

https://pattern.bio

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Pattern Bioscience is an Austin-based clinical diagnostics company developing a culture-free single-cell microbiology platform that delivers rapid pathogen identification and antimicrobial susceptibility testing for hospital microbiology labs treating critically ill patients.

Ownership category

akta.pro rank

Product category

Clinical Microbiology Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)

akta.pro secondary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Rapid antimicrobial susceptibility testing
• Clinical microbiology diagnostics
• Single-cell microbiology platform
• Bacterial pathogen identification
• Antimicrobial resistance diagnostics

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Platform and Assays: Pattern Bioscience generates revenue through the sale of its single-cell microbiology diagnostic system and associated ID/AST assay panels (Pneumonia ID/AST Panel, Bacteremia ID/AST Panel). The company is pre-commercial as of early 2026, preparing for first U.S. commercial launch following FDA 510(k) clearance of the Pneumonia ID/AST Panel.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Pattern Bioscience develops and plans to commercialize a single-cell microbiology (Digital Culture™) diagnostic platform that isolates individual live bacterial cells in picovolume-scale droplets and uses machine learning to interpret their metabolic patterns. The platform is intended to deliver pathogen identification and phenotypic antimicrobial susceptibility testing (ID/AST) directly from clinical specimens in hours instead of the 2–4 days required by traditional culture-based methods. Initial commercial products target the Pneumonia ID/AST Panel for critically ill pneumonia patients and the Bacteremia ID/AST Panel for bloodstream infections, sold to hospital clinical microbiology laboratories.

Product overview

Pattern Bioscience offers a single-cell microbiology platform as its core technology, with two primary test panels: the Pneumonia ID/AST Panel for respiratory infections and the Bacteremia ID/AST Panel for bloodstream infections. The platform bypasses traditional culture steps by isolating and analyzing individual bacterial cells captured in droplets, delivering rapid pathogen identification and phenotypic antimicrobial susceptibility results in hours rather than days. The Pneumonia Panel analyzes bacterial cells directly from respiratory specimens, while the Bacteremia Panel works directly from positive blood culture samples.

Differentiator

Problem solved

Functional benefit

Products and services

• Pattern Pneumonia ID/AST Panel Rapid identification and phenotypic antimicrobial susceptibility testing (ID/AST) panel designed for critically ill patients hospitalized with severe pneumonia, delivering pathogen ID and susceptibility results in hours rather than the 2–4 days required by culture-based methods. Analyzes bacterial cells directly from respiratory specimens using single-cell microbiology, and received FDA Breakthrough Device Designation in December 2021.
• Pattern Bacteremia ID/AST Panel Identification and phenotypic antibiotic susceptibility testing panel designed to identify pathogens and provide AST directly from positive blood culture samples, eliminating the need for additional culturing and isolation steps to obtain faster phenotypic susceptibility results for bloodstream infections.
• Single-Cell Microbiology (Digital Culture™) Diagnostic Platform Culture-free, rapid phenotypic testing platform that delivers clinically actionable bacterial identification and antimicrobial susceptibility results in hours. Uses single-cell isolation in picovolume-scale droplets combined with proprietary data science and machine learning to generate millions of measurements per run capturing all resistance mechanisms (known, unknown, genetic, epigenetic, simple, or complex) for the company's ID/AST panels.

Quantifiable outcome

• Up to 50% of antibiotics prescribed in hospitals are unnecessary or inappropriate (CDC)
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Accelerate Diagnostics: Direct competitor developing rapid phenotypic ID/AST for bloodstream and other serious infections; acquired by bioMérieux in 2022. Competes head-to-head with Pattern on the same hospital bench for time-to-AST in critical care settings.
• Specific Diagnostics: Developed a rapid AST instrument using metabolomic signaling — the closest analogue to Pattern's single-cell approach. Acquired by bioMérieux in 2022; Pattern's VP Sales led sales at Specific prior to the acquisition.
• Qvella Corporation: Early-stage company developing rapid culture-free ID/AST directly from positive blood cultures, addressing the same unmet need as Pattern's Bacteremia ID/AST Panel and Bacteremia product roadmap.
• Selux Diagnostics: Develops rapid phenotypic AST to deliver antibiotic susceptibility results in hours directly from clinical samples; competed against Pattern in the AMR Diagnostics Challenge and operates in the same FDA Breakthrough Designation / sepsis-decision-making category.
• T2 Biosystems: Develops T2Bacteria and T2Candida panels for direct-from-blood rapid identification without culture; overlaps with Pattern's bloodstream infection roadmap and the clinical unmet need around sepsis diagnostics.

Broad incumbents

• bioMérieux: Global leader in clinical microbiology (VITEK, BIOFIRE FilmArray, BACT/ALERT). Acquired both Accelerate Diagnostics and Specific Diagnostics. Sets the reimbursement and workflow precedent Pattern's commercial team must navigate.
• Becton Dickinson (BD): Broad diagnostics incumbent offering the BD MAX molecular platform, BD Phoenix automated AST, and established MALDI workflow partnerships. Competes across ID/AST categories where Pattern plans to expand.
• Bruker Corporation: Operates the MALDI Biotyper, the dominant rapid MALDI-TOF identification workflow in clinical microbiology labs; the incumbent alternative to single-cell phenotypic ID that Pattern's Pneumonia Panel must displace or complement.
• Cepheid (Danaher): GeneXpert and Xpress systems are rapidly deployed across U.S. hospital microbiology labs for molecular diagnostics, including for bloodstream and respiratory panels, and represent the typical workflow that Pattern's phenotypic approach must clinically displace.
• Roche Diagnostics: Acquired GenMark Diagnostics (eXpert rapid molecular) for ~$1.8B and operates cobas/coba platforms spanning microbiology and infectious disease; relevant as the strategic acquirer archetype for novel hospital diagnostics with KOL-led commercial traction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/patternbio
• LinkedInlinkedin.com/company/patternbio
• Facebookfacebook.com/PatternBio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pattern Bioscience